Reichert Technologies – Life Sciences Showcasing Phage Antibody Research and SPR at Antibody Engineering and Therapeutics San Diego, December 12th - 15th, Booth #216

Share Article

Reichert Technologies, a business unit of AMETEK Ultra Precision Technologies, will take part in the Antibody Engineering and Therapeutics Summit, December 12th – December 15th, 2016 in San Diego, CA.


In addition to displaying the Reichert4SPR, a new 4-channel surface plasmon resonance instrument, Reichert will present “A Preliminary Investigation of Phage Antibody Enrichment Using Reichert SPR Systems” a scientific poster session on Monday, the 12th from 1pm to 3pm. Dr. Mark Sullivan from the University of Rochester conducted the research for this poster.

The poster outlines how utilizing a Reichert SPR system improves the efficiency of phage antibody isolation and characterization. The idea of using an SPR instrument to function as both a lab-on a chip, to permit semi-automated manipulation of phage preparations, as well as providing the SPR signal as a window on the binding and enrichment of high affinity variants of scFvs or Fabs (or other scaffolds) is appealing, and could lead to a significant competitive advantage in the expanding market for therapeutic antibodies. The goal is to demonstrate a novel use of the Reichert SPR instrument to perform enrichment of phage antibodies using the fluidics system of the instrument.

Why is this important? If successfully applied, this new approach would dramatically reduce the time for enrichment cycles, enable multiple enrichments to be performed in parallel, and improve control and repeatability of the process. Throughput could be increased by as much as 6x vs traditional approaches.

Visitors should stop by booth #216 to learn more.

About Reichert’s Full Line of SPR Systems

Reichert's SPR systems provide the diverse interests of academia and industry with the most cost-effective, sensitive and flexible platforms in today's marketplace. These systems supply a comprehensive characterization of molecular interactions that are important to researchers in numerous scientific disciplines, including drug discovery. These interactions include but are not limited to protein–protein, protein–peptide, protein–nucleic acid and protein–small molecule.

Reichert systems generate information-rich data to determine such key parameters as binding association and dissociation rate constants (kinetics), equilibrium (affinity) constants, thermodynamics and concentration. The systems give invaluable insight into the dynamics of protein-binding assays that govern chemical and biological processes. The new four-channel Reichert4SPR system’s leading technology delivers lower baseline drift and improved sensitivity.

About Antibody Engineering and Therapeutics Summit

The Antibody Engineering & Therapeutics program is designed in collaboration with the most respected scientists in the field. It’s the largest meeting bringing you the latest science, technologies and partners needed to accelerate next generation antibodies towards commercial success.

About Dr. Mark Sullivan

Dr. Sullivan, Research Assistant Professor, Department of Microbiology and Immunology. Director, Biomolecular Interaction Laboratory, University of Rochester. The ability to rapidly isolate human antibodies using phage display has opened up new approaches to understanding protein function. Research in my laboratory is focused on the manipulation of immunoglobulin molecules to develop novel reagents for characterization of protein expression and structure. We are using phage antibody technology in several areas of proteomics research to develop improved reagents for protein characterization as well as novel inhibitors of protein function that will aid in defining the roles of the many new proteins discovered through genomic sequencing. Major efforts are aimed at dissecting the saliva proteome and developing panels of antibodies for incorporation into new diagnostic platforms using protein microarrays.

A second initiative is to derive antibodies useful for solving the structure of proteins by X-ray crystallography. Additional studies focus on the therapeutic potential of single-chain antibodies to reduce protein aggregation and misfolding, a process that characterizes a variety of neurodegenerative diseases.

About Reichert Life Sciences

Reichert Life Sciences’ entry into the design and manufacturing of Surface Plasmon Resonance (SPR) instrumentation began in 1997 with efforts to incorporate bio-sensing technology into Reichert's core critical angle refractometer products. This technology built upon a key Reichert patent (US Patent #4,640,616) describing a digital reflected light refractometer incorporating a charge-coupled device to sense reflected light intensity over a range of angles covering a refractive index range from 1.33 to 1.52. Since then, Reichert has utilized its applications knowledge to develop a full line of SPR systems that push the limits of detection and sensitivity in label-free interaction analysis with technology that drives research from discovery to development to production. Since Reichert’s first SPR device was sold in 2000, the company’s equipment has been used in hundreds of published studies.

About Reichert Technologies

With more than 150 years of history, Reichert Technologies of Buffalo, New York, is a global leader in the design, development, manufacture and sale of analytical and life science instruments, ophthalmic, and medical devices. Reichert also offers laboratory and portable/field refractometers for the automotive, food and beverage, chemical and industrial markets as well as clinical instrumentation for the healthcare market.

About AMETEK, Inc.

Reichert Technologies is a unit of AMETEK Ultra Precision Technologies, a division of AMETEK, Inc., is a global leader in electronic instruments and electromechanical devices.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jennifer Carlo
since: 01/2014
Follow >